IGXTライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (27 4月 2024 @ 04:04):

IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market...

Stats
本日の出来高	60 179.00
平均出来高	90 185.00
時価総額	28.64M
EPS	$0 ( 2024-03-21 )
次の収益日	( $0 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.73
ATR14	$0.00400 (2.44%)

Insider Trading

Date	Person	Action	Amount	type
2023-11-28	Atai Life Sciences N.v.	Buy	4 053 750	Warrant (Right to Buy)
2024-03-08	Atai Life Sciences N.v.	Buy	1 000 000	Convertible Notes
2023-10-06	Atai Life Sciences N.v.	Buy	8 500 000	Convertible Notes
2024-03-08	Atai Life Sciences N.v.	Buy	4 000 000	Warrant (Right to Buy)
2023-11-28	Atai Life Sciences N.v.	Buy	750 000	Convertible Promissory Note

INSIDER POWER
99.00
Last 94 transactions
Buy: 34 722 521 \| Sell: 605 000

IntelGenx Technologies 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

IntelGenx Technologies 財務諸表

Annual	2023
収益:	$1.04M
総利益:	$-1.46M (-140.52 %)
EPS:	$-0.0568

FY	2023
収益:	$1.04M
総利益:	$-1.46M (-140.52 %)
EPS:	$-0.0568

FY	2022
収益:	$950 000
総利益:	$-908 000 (-95.58 %)
EPS:	$-0.0726

FY	2021
収益:	$1.54M
総利益:	$-721 000 (-46.97 %)
EPS:	$-0.0700

Financial Reports:

No articles found.

IntelGenx Technologies

IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 for adult use; INT0007/2006, an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral film containing montelukast for treatment of Alzheimer; INT0027/2011 to treat opioid addition; INT0010/2006 for treatment of neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, an oral film product for schizophrenia or bipolar 1 disorder; and INT0048/2020 for animal health. It is also developing INT0039/2013, INT0040/2014, INT0052/2020, INT0053/2020, and INT0054/2020. The company has licensing, development, and supply agreement with Tilray, Inc.; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.